Logo

Digipure 2018 - Management of Major depressive disorder
  This presentation will begin on Wednesday, 14 November 2018 at 15:00 UK Time
 
Time Topic Speaker
5 min Introduction & Welcome note Dr. Gustavo Fischbein
Neurosciences Regional Medical Expert - Emerging Markets, GSK
20 min Major Depressive Disorder:
Network Meta-analysis of 21 antidepressants – Methodology and clinical implications 
Dr. Andrea Cipriani
20 min Q&A
Dr. Andrea Cipriani
  Test Your System
 Help
  Adverse event should be reported.
Local reporting information can be found at: http://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/

Your privacy is important to us. Please read our Privacy Statement for details.

© 2001-2018 GSK group of companies. All rights reserved.

GlaxoSmithKline plc. Registered in England and Wales No. 3888792. Registered office: 980 Great West Rd, Brentford, Middlesex, TW8 9GS, United Kingdom.
  Zinc Code: CEM/LTG/0075/18 - Date of Preparation : October 2018



Dr Cipriani, MD PhD

NIHR Research Professor in Department of Psychiatry, University of Oxford, Warneford Hospital and Associate Director, Research and Development Department, Oxford Health NHS Foundation Trust.

He has over 20 years of clinical experience. His research interests include systematic reviews and meta-analysis, randomised controlled trials and epidemiological psychiatry. He sits on the editorial boards of renowned journals like BMJ, Lancet, British Journal of Psychiatry etc. He is actively involved in various research projects and has published around 200 articles in peer reviewed journal, authored five book chapters and one book. He has undertaken various teaching assignments for undergraduate and postgraduate students from various specialties including medical, physiotherapy, nursing and neurology. Dr. Cipriani is the lead author for a recently published landmark publication on network meta-analysis of 21 antidepressants in acute treatment of MDD in adults.